ArticleJournal for immunotherapy of cancer2021

Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES).

Peter Kar Han Lau et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.